var data={"title":"Valganciclovir: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Valganciclovir: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7136?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=valganciclovir-drug-information\" class=\"drug drug_general\">see &quot;Valganciclovir: Drug information&quot;</a> and <a href=\"topic.htm?path=valganciclovir-patient-drug-information\" class=\"drug drug_patient\">see &quot;Valganciclovir: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708869\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hematologic toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, and bone marrow failure including aplastic anemia have been reported in patients treated with valganciclovir.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Impairment of fertility:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Based on animal data, valganciclovir may cause temporary or permanent inhibition of spermatogenesis in males and suppression of fertility in females.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Fetal toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Based on animal data, valganciclovir has the potential to cause birth defects in humans.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Mutagenesis and carcinogenesis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Based on animal data, valganciclovir has the potential to cause cancers in humans.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232941\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Valcyte</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232942\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Valganciclovir;</li>\n      <li>Valcyte</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2797950\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiviral Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11445213\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Congenital CMV infection; treatment:</b> Limited data available: GA &ge;32 weeks and &ge;1.8 kg : Oral: 16 mg/kg/dose every 12 hours for 6 months (Acosta 2007; Bradley 2015; DHHS [pediatric] 2013; Kimberlin 2008, Kimberlin 2015,  <i>Red Book</i> [AAP 2012]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Initial neonatal dose determination based on pharmacokinetic studies of 24 neonates (GA: 34 to 41 weeks; PNA at time of therapy initiation: &ge;6 days) which demonstrated that 16 mg/kg/dose twice daily produced similar serum concentrations to ganciclovir 6 mg/kg intravenously twice daily with a 6 week recommended duration of therapy based on ganciclovir experience (Acosta 2007; DHHS [pediatric] 2013, Kimberlin 2008, <i>Red Book</i> [AAP 2012).  A longer duration of therapy (6 months) was evaluated in a randomized trial of 96 neonates (GA &gt;32 weeks weighing &ge;1,800 g; PNA  at time of therapy initiation &lt;30 days) which compared treatment with 6 weeks of therapy (n=47) to 6 months of therapy (n=49); results demonstrated a modest improvement in long-term hearing and developmental outcomes (evaluated at 12 and 24 months of age) with the longer duration of therapy (6 month course); however, short-term improvement (evaluated at 6 months of age) in hearing was not demonstrated (Kimberlin 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2797981\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=valganciclovir-drug-information\" class=\"drug drug_general\">see &quot;Valganciclovir: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Valganciclovir tablets and ganciclovir capsules cannot be substituted on a mg-per-mg basis since they are NOT BIOEQUIVALENT. In pediatric patients, valganciclovir oral solution is the preferred oral dosage form in pediatric patients for accuracy in dosing; valganciclovir tablets can be considered if the calculated dose is within 10% of the available tablet strength (450 mg). In pediatric patients, dosing may be based on either BSA (mg/m<sup>2</sup>) or weight (mg/kg); use extra precaution to verify dosing parameters during calculations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Congenital CMV infection; treatment (continuation from neonatal period):</b> Limited data available: Infants 1 to 6 months: Oral: 16 mg/kg/dose every 12 hours for 6 months; dosing based on a pharmacokinetic study of 24 neonates demonstrated that 16 mg/kg/dose twice daily produced similar serum concentrations to ganciclovir 6 mg/kg intravenously twice daily with a 6-week recommended duration of therapy based on ganciclovir experience (Acosta 2007; DHHS [pediatric] 2013; Kimberlin 2008; <i>Red Book</i> [AAP 2012]).  A longer duration of therapy (6 months) was evaluated in a randomized trial of 96 neonates (GA &gt;32 weeks weighing &ge;1.8 kg; PNA  at time of therapy initiation &lt;30 days) which compared treatment with 6 weeks of therapy (n=47) to 6 months of therapy (n=49); results demonstrated a modest improvement in long-term hearing and developmental outcomes (evaluated at 12 and 24 months of age) with the longer duration of therapy (6 month course); however, short-term  improvement (evaluated at 6 months of age) in hearing was not demonstrated  (Kimberlin 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prevention of CMV disease:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <span style=\"text-decoration: underline\">Following solid organ transplantation: </span></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Heart transplantation:</i> Begin therapy within 10 days of transplantation; continue therapy until 100 days post transplantation. Doses should be rounded to the nearest 10 mg increment;  maximum daily dose: 900 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants, Children, and Adolescents 1 month to 16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Once daily dose (mg) = 7 x body surface area x creatinine clearance*</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adolescents &ge;17 years: 900 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Kidney transplantation:</i> Begin therapy within 10 days of transplantation; continue therapy until 200 days post transplantation or 100 days post transplantation if kidney-pancreas transplant in adolescents &ge;17 years. Doses should be rounded to the nearest 10 mg increment; maximum daily dose: 900 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants, Children, and Adolescents 4 months to 16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Once daily dose (mg) = 7 x body surface area x creatinine clearance*</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adolescents &ge;17 years: 900 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Liver transplantation:</i> Limited data available: Infants, Children, and Adolescents 4 months to 16 years (Kotton 2013; Lapidus-Krol 2010; Vaudry 2009): <b>Note:</b> In adults, studies in liver transplant patients reported a higher incidence of tissue-invasive CMV with valganciclovir relative to oral ganciclovir. In pediatric trials, therapy was initiated within 10 days  of transplantation and continued therapy until 100 days post transplantation (Vaundry 2009); maximum daily dose: 900 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Once daily dose (mg) = 7 x body surface area x creatinine clearance*</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <span style=\"text-decoration: underline\">HIV-exposed/-positive:</span> Infants, Children, and Adolescents 4 months to 16 years (DHHS [pediatric] 2013):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Once daily dose (mg) = 7 x body surface area x creatinine clearance*</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Consider therapy initiation for children &lt;6 years of age who are CMV-seropositive and have a CD4 percentage &lt;5% of and for children &ge;6 years of age who are CMV-seropositive and have CD4 cell counts &lt;50 cells/mm<sup>3</sup>. Consider cessation of therapy when CD4 cell count is &gt;10% in children &lt;6 years of age and &gt;100 cells/mm<sup>3</sup> for children &ge;6 years of age; maximum daily dose: 900 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <span style=\"text-decoration: underline\">* Creatinine clearance calculation (based on the modified Schwartz formula):</span></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl (mL/minute/1.73 m<sup>2</sup>) = [k x height (cm)] &divide; serum creatinine (mg/dL)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> If the calculated CrCl is &gt;150 mL/minute/1.73 m<sup>2</sup>, then a maximum value of 150 mL/minute/1.73 m<sup>2</sup> should be used to calculate the dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Calculated using a modified Schwartz formula where k =</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&bull; 0.33 in infants &lt;1 year of age with low birthweight for gestational age</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&bull; 0.45 in infants &lt;1 year of age with birthweight appropriate for gestational age</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&bull; 0.45 in children 1 year to &lt;2 years</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&bull; 0.55 in boys age 2 to &lt;13 years</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&bull; 0.55 in girls age 2 to &lt;16 years</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&bull; 0.7 in boys age 13 to 16 years</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>CMV retinitis; treatment:</b> Adolescents (DHHS [adult] 2013): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Induction (active retinitis): 900 mg twice daily for 14 to 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: Following induction treatment or for patients with inactive CMV retinitis who require maintenance therapy: 900 mg once daily for at least 3 to 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>CMV retinitis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Induction: 900 mg twice daily for 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: Following induction treatment or for patients with inactive CMV retinitis who require maintenance therapy: 900 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prevention of CMV disease following transplantation:</b> Oral: 900 mg once daily beginning within 10 days of transplantation; continue therapy until 100 days (heart or kidney-pancreas transplant) or 200 days (kidney transplant) post transplantation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents 1 month to 16 years: No additional dosage adjustments required; use of equation adjusts for renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &gt;16 years and Adults (tablet formulation):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Induction dose:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;60 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 40 to 59 mL/minute: 450 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 25 to 39 mL/minute: 450 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 24 mL/minute: 450 mg every 2 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Manufacturer's labeling: Use not recommended; ganciclovir (with appropriately specified renal dosage adjustment) should be used instead of valganciclovir</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Alternate recommendations: HIV-1 infected persons: Consider valganciclovir solution 200 mg 3 times weekly (Lucas 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">End stage renal disease (ESRD) on intermittent hemodialysis (IHD):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Manufacturer's labeling: Use not recommended; ganciclovir (with appropriately specified renal dosage adjustment) should be used instead of valganciclovir</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Alternate recommendations: HIV-1 infected persons: Consider valganciclovir solution 200 mg 3 times weekly (Lucas 2014); valganciclovir is dialyzable and should be administered following dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance/prevention dose:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;60 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 40 to 59 mL/minute: 450 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 25 to 39 mL/minute: 450 mg every 2 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 24 mL/minute: 450 mg twice weekly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Manufacturer's labeling: Use not recommended; ganciclovir (with appropriately specified renal dosage adjustment) should be used instead of valganciclovir</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Alternate recommendations: HIV-infected persons: Consider valganciclovir solution 100 mg 3 times weekly (Lucas 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">End stage renal disease (ESRD) on intermittent hemodialysis (IHD):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Manufacturer's labeling: Use not recommended; ganciclovir (with appropriately specified renal dosage adjustment) should be used instead of valganciclovir</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Alternate recommendations: HIV-1 infected persons: Consider valganciclovir solution 100 mg 3 times weekly (Lucas 2014); valganciclovir is dialyzable and should be administered following dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232917\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Valcyte: 50 mg/mL (88 mL) [contains saccharin sodium, sodium benzoate; tutti-frutti flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/mL (88 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Valcyte: 450 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 450 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232903\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2797982\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Due to the carcinogenic and mutagenic potential, avoid direct contact with broken or crushed tablets, powder for oral solution, and oral solution. Consideration should be given to handling and disposal according to guidelines issued for antineoplastic drugs; however, there is no consensus on the need for these precautions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer with meals. The preferred dosage form for pediatric patients is the oral solution; however, valganciclovir tablets may be used as long as the calculated dose is within 10% of the available tablet strength (450 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution: Prepare the oral solution by adding 91 mL of purified water to the bottle; shake well; a reconstituted 100 mL bottle will only provide 88 mL of solution for administration </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132847\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232936\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution: Store dry powder at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Store reconstituted oral solution at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Discard any unused medication after 49 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2797951\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Prevention of CMV disease in high-risk patients undergoing heart transplantation (FDA approved in ages 1 month to 16 years and adults); prevention of CMV disease in high-risk patients undergoing kidney transplantation (FDA approved in ages 4 months to 16 years and adults); treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) (FDA approved in adults); prevention of CMV disease in high-risk patients (donor CMV positive/recipient CMV negative) undergoing kidney/pancreas transplantation (FDA approved in adults); has also been used for prevention of CMV disease in high-risk pediatric patients undergoing BMT or hematopoietic stem cell transplant, solid organ transplants other than those indicated above, prevention of CMV disease in HIV-exposed/-positive patients, and treatment of congenital CMV disease </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232970\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Valcyte may be confused with Valium, Valtrex</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ValGANciclovir may be confused with acyclovir, valACYclovir, ganciclovir</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50524175\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac arrhythmia, hypertension, hypotension, peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Agitation, anxiety, chills, confusion, depression, dizziness, fatigue, hallucination, headache, insomnia, malaise, pain, paresthesia, peripheral neuropathy, psychosis, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Cellulitis, dermatitis, increased wound secretion, night sweats, pruritus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyperkalemia, hypophosphatemia, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distention, abdominal pain, constipation, decreased appetite, diarrhea, dysgeusia, dyspepsia, nausea, oral mucosa ulcer, pancreatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Hematuria, reduced fertility, urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, bone marrow depression (including aplastic anemia), febrile neutropenia, hemorrhage (associated with thrombocytopenia), neutropenia, pancytopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatic insufficiency, increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Graft rejection, organ transplant rejection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Candidiasis (including oral candidiasis), influenza, sepsis, wound infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, limb pain, muscle spasm, myalgia, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Eye pain, macular edema, retinal detachment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Deafness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Decreased creatinine clearance, increased serum creatinine, renal failure, renal impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough, dyspnea, pharyngitis (including nasopharyngitis), upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever, postoperative complication, postoperative pain, wound dehiscence</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Agranulocytosis, anaphylaxis, granulocytopenia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232922\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (eg, anaphylaxis) to valganciclovir, ganciclovir, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to acyclovir or valacyclovir</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232907\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute renal failure: Acute renal failure may occur; ensure adequate hydration and use with caution in patients receiving concomitant nephrotoxic agents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood dyscrasias: <b>[US Boxed Warning]: Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, and bone marrow failure, including aplastic anemia have been reported.</b> May occur at any time during treatment and worsen with continued use; cell counts usually begin to recover within 3 to 7 days of treatment discontinuation. Do not use in patients with an absolute neutrophil count &lt;500 cells/mm<sup>3</sup>, platelet count &lt;25,000/mm<sup>3</sup>, or hemoglobin &lt;8 g/dL; use with caution in patients with preexisting bone marrow suppression, cytopenias, or in those receiving myelosuppressive drugs/irradiation. Monitor CBC and platelet count at baseline and frequently during therapy, especially in patients with renal impairment, those with previous drug-induced leukopenia, and those with neutrophil counts &lt;1,000 cells/mm<sup>3</sup> at treatment initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Carcinogenic/teratogenic: <b>[US Boxed Warning]: May cause temporary or permanent inhibition of spermatogenesis and suppression of fertility; has the potential to cause birth defects and cancers in humans.</b> Due to its teratogenic potential, females should undergo pregnancy testing prior to initiation and use effective contraception during treatment and for 30 days after; males should use barrier contraception during treatment and for 90 days after.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with impaired renal function; dosage adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Acute renal failure may occur in elderly patients with or without preexisting renal impairment; use with caution and adjust dose as needed based on renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Liver transplant recipients: Not indicated for use in liver transplant patients (higher incidence of tissue-invasive cytomegalovirus [CMV] relative to oral ganciclovir was observed in trials).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: The preferred dosage form for pediatric patients is the oral solution; however, valganciclovir tablets may be used so long as the calculated dose is within 10% of the available tablet strength (450 mg). Use of valganciclovir for the treatment of congenital CMV disease has not been evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27975762\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The rates of certain adverse events and laboratory abnormalities, such as upper respiratory tract infection, pyrexia, nasopharyngitis, anemia, and neutropenia, were reported more frequently in pediatric patients than in adults in clinical trials. In a 6-month trial evaluating congential CMV treatment in neonates and infants, the reported incidence of grade 3 or 4 neutropenia was similar between valganciclovir and placebo (21% vs 27%) (Kimberlin 2015). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300203\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232911\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13002&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: Ganciclovir-Valganciclovir may enhance the nephrotoxic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Ganciclovir-Valganciclovir may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: Ganciclovir-Valganciclovir may increase the serum concentration of Didanosine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imipenem: Ganciclovir-Valganciclovir may enhance the adverse/toxic effect of Imipenem. Specifically, the risk of seizures may be increased.  Management: Avoid concomitant use of these agents unless the prospective benefits of therapy outweigh the risks.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: May increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Mycophenolate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Ganciclovir-Valganciclovir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Products: May increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenofovir Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: Ganciclovir-Valganciclovir may enhance the adverse/toxic effect of Zidovudine. Specifically, hematologic toxicity may be enhanced. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232937\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Coadministration with a high-fat meal increased AUC by 30%. Management: Valganciclovir should be taken with meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232925\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">\n      <b>[US Boxed Warning]: May cause temporary or permanent inhibition of spermatogenesis and suppression of fertility; has the potential to cause birth defects in humans.</b> Valganciclovir is converted to ganciclovir and shares its reproductive toxicity. Ganciclovir crosses the placenta. Based on animal data, temporary or permanent impairment of fertility may occur in males and females. Ganciclovir is also teratogenic in animals. The manufacturer recommends females of reproductive potential undergo pregnancy testing prior to therapy. Females should use effective contraception during treatment and for 30 days after; males should use barrier contraception during treatment and for 90 days after.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Adverse events following congenital cytomegalovirus (CMV) infection may also occur. Hearing loss, mental retardation, microcephaly, seizures, and other medical problems have been observed. The indications for treating CMV retinitis during pregnancy are the same as in non-pregnant HIV infected woman; however systemic therapy should be avoided during the first trimester when possible. Use of valganciclovir is recommended to treat maternal infection, but not recommended for the treatment of asymptomatic maternal disease for the sole purpose of preventing infant infection. Monitoring of the fetus is recommended. Current recommendations for use of valganciclovir in HIV infected pregnant women are based on data from ganciclovir use in pregnant women following organ transplant or use late in pregnancy in non-HIV infected women (HHS [OI adult 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2797983\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Retinal exam at least every 4 to 6 weeks when treating CMV retinitis; CBC with differential, platelet count, serum creatinine at baseline and periodically during therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232906\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Valganciclovir is rapidly converted to ganciclovir in the body. Ganciclovir is phosphorylated to a substrate which competitively inhibits the binding of deoxyguanosine triphosphate to DNA polymerase resulting in inhibition of viral DNA synthesis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232921\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Well absorbed; high-fat meal increases AUC by 30%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: Ganciclovir: 0.7 L/kg; widely to all tissue including CSF and ocular tissue</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Ganciclovir: 1% to 2%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Converted to ganciclovir by intestinal mucosal cells and hepatocytes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: With food: 60%; similar in pediatric patients 4 months to 16 years; neonates: Initial data: 54% (Acosta 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients (heart, kidney, or liver transplant): Mean range:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">4 months to 2 years: 2.8 to 4.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">2 to 12 years: 2.8 to 3.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">12 to 16 years: 4.9 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ganciclovir: 4.08 hours; prolonged with renal impairment; Severe renal impairment: Up to 68 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Heart, kidney, kidney-pancreas, or liver transplant patients: Mean range: 6.18 to 6.77 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Ganciclovir: 1.7 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (80% to 90%; primarily as ganciclovir)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25504019\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> A pharmacokinetic study of 10 solid organ and stem cell transplant patients (8 months to 13 years) found that 20 mg/kg/day of oral valganciclovir produced a similar ganciclovir exposure as 10 mg/kg/day of IV ganciclovir (Launay 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10893687\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;\">\n      <b>Note:</b> Commercial preparation is available (50 mg/mL)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A 60 mg/mL oral suspension may be with tablets and a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg;. Crush sixteen 450 mg tablets and reduce to a fine powder. Add 1 mL portions of chosen vehicle (10 mL total) and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 120 mL; transfer to a calibrated amber glass bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label &quot;shake well&quot; and &quot;refrigerate&quot;. Stable for 35 days refrigerated.</p>\n    <div class=\"reference\">Henkin CC, Griener JC, and Ten Eick AP, &quot;Stability of Valganciclovir in Extemporaneously Compounded Liquid Formulations,&quot; <i>Am J Health Syst Pharm</i>, 2003, 60(7):687-90.<span class=\"pubmed-id\">12701551</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232924\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Valcyte Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (88 mL): $1,284.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (ValGANciclovir HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (88 mL): $1,000.33</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Valcyte Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">450 mg (60): $6,364.97</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (ValGANciclovir HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">450 mg (60): $3,863.81</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232928\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ganzos (LK);</li>\n      <li>Rovalcyte (FR);</li>\n      <li>RoValcyte (PT);</li>\n      <li>Vagacyte (LK);</li>\n      <li>Valcyte (AE, AT, AU, BB, BE, BG, BH, BR, CH, CN, CR, CY, CZ, DE, DK, DO, EE, ES, FI, GB, GR, GT, HN, HR, IE, IL, IS, IT, JO, KR, KW, LB, LK, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PH, PL, QA, RO, SA, SE, SG, SI, SK, SV, TH, TR, TW, VN);</li>\n      <li>Valixa (AR, CL, CO, JP, PE, PY, UY, VE);</li>\n      <li>Valtsyt (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Acosta EP, Brundage RC, King JR, et al, &quot;Ganciclovir Population Pharmacokinetics in Neonates Following Intravenous Administration of Ganciclovir and Oral Administration of a Liquid Valganciclovir Formulation,&quot; <i>Clin Pharmacol Ther</i>, 2007, 81(6):867-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valganciclovir-pediatric-drug-information/abstract-text/17392728/pubmed\" target=\"_blank\" id=\"17392728\">17392728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Cantery JB, et al, eds. <i>Nelson's Pediatric Microbial Therapy</i>. 21st ed. American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,&quot; <i>MMWR Recomm Rep</i>, 2009, 58(RR-11):1-166.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valganciclovir-pediatric-drug-information/abstract-text/19730409/pubmed\" target=\"_blank\" id=\"19730409\">19730409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clark BS, Chang IF, Karpen SJ, et al, &quot;Valganciclovir for the Prophylaxis of Cytomegalovirus Disease in Pediatric Liver Transplant Recipients,&quot; <i>Transplantation</i>, 2004, 77(9):1480.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valganciclovir-pediatric-drug-information/abstract-text/15167619/pubmed\" target=\"_blank\" id=\"15167619\">15167619</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections (OI) in HIV-Infected Adults and Adolescents. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA). May 7, 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 6, 2013. Available at <a href=\"http://aidsinfo.nih.gov%20/\" target=\"_blank\">http://aidsinfo.nih.gov </a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Galli L, Novelli A, Chiappini E, et al, &quot;Valganciclovir for Congenital CMV Infection: A Pilot Study on Plasma Concentration in Newborns and Infants,&quot; <i>Pediatr Infect Dis J</i>, 2007, 26(5):451-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valganciclovir-pediatric-drug-information/abstract-text/17468661/pubmed\" target=\"_blank\" id=\"17468661\">17468661</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kimberlin DW, Acosta EP, S&aacute;nchez PJ, et al, &quot;Pharmacokinetic and Pharmacodynamic Assessment of Oral Valganciclovir in the Treatment of Symptomatic Congenital Cytomegalovirus Disease,&quot; <i>J Infect Dis</i>, 2008, 197(6):836-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valganciclovir-pediatric-drug-information/abstract-text/18279073/pubmed\" target=\"_blank\" id=\"18279073\">18279073</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kimberlin DW, Jester PM, S&aacute;nchez PJ, et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. <i>N Engl J Med</i>. 2015;372(10):933-943.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valganciclovir-pediatric-drug-information/abstract-text/25738669 /pubmed\" target=\"_blank\" id=\"25738669 \">25738669 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Launay E, Th&eacute;&ocirc;ret Y, Litalien C, et al. Pharmacokinetic profile of valganciclovir in pediatric transplant recipients. <i>Pediatr Infect Dis J</i>. 2012;31(4):405-407.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valganciclovir-pediatric-drug-information/abstract-text/22198827/pubmed\" target=\"_blank\" id=\"22198827\">22198827</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lombardi G, Garofoli F, Villani P, et al, &quot;Oral Valganciclovir Treatment in Newborns With Symptomatic Congenital Cytomegalovirus Infection,&quot; <i>Eur J Clin Microbiol Infect Dis</i>, 2009, 28(12):1465-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valganciclovir-pediatric-drug-information/abstract-text/19763643/pubmed\" target=\"_blank\" id=\"19763643\">19763643</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucas GM, Ross MJ, Stock PG, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(9):e96-138.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valganciclovir-pediatric-drug-information/abstract-text/25234519 /pubmed\" target=\"_blank\" id=\"25234519 \">25234519 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peyriere H, Jeziorsky E, Jalabert A, et al, &quot;Neurotoxicity Related to Valganciclovir in a Child With Impaired Renal Function: Usefulness of Therapeutic Drug Monitoring,&quot; Ann Pharmacother, 2006, 40(1):143-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valganciclovir-pediatric-drug-information/abstract-text/16368917 /pubmed\" target=\"_blank\" id=\"16368917 \">16368917 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Valcyte (valganciclovir hydrochloride) [prescribing information]. South San Fransisco, CA: Genentech USA, Inc; April 2015.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13002 Version 142.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708869\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F232941\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F232942\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F2797950\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11445213\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F2797981\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F232917\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F232903\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2797982\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132847\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F232936\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F2797951\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F232970\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F50524175\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F232922\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F232907\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F27975762\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300203\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F232911\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F232937\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F232925\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F2797983\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F232906\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F232921\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F25504019\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F10893687\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F232924\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F232928\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13002|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=valganciclovir-drug-information\" class=\"drug drug_general\">Valganciclovir: Drug information</a></li><li><a href=\"topic.htm?path=valganciclovir-patient-drug-information\" class=\"drug drug_patient\">Valganciclovir: Patient drug information</a></li></ul></div></div>","javascript":null}